pharmaphorum Top Stories 16 September 2024
pharmaphorum
Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency
It was another policy-heavy week in pharma as both the USA and UK made some moves and some noise.
In the UK, the new health secretary has released a blistering report about the state of the NHS and NICE has cleared a rare disease treatment from MSD. And in the US, the BIOSECURE Act, which could have huge implications for US-Chinese relations in biotech, has passed through the House of Representatives and is heading for the Senate.
And at last week's Presidential debate, pharma was somewhat overshadowed by the pet-eating discourse, but we found a few tidbits for the life sciences crowd. All this, plus a new manufacturing investment from Lily, in today's Top Stories roundup.
Catch up below and at pharmaphorum.com!
Top Stories
NHS is in "serious trouble" says Darzi report
A report on the state of the NHS in England by former Labour Health Minister Lord Darzi has concluded that it is in a dire state – which will come as a surprise to nobody – and has problems that could take up to eight years to fix. READ MORE
Lilly ramps up Irish manufacturing investment by $1bn
礼来 has added $1 billion to its investment plan for a new manufacturing facility in Ireland that will be used to produce its Alzheimer's therapy donanemab. READ MORE
BIOSECURE Act clears House vote
The US House of Representatives comprehensively voted in favour of the BIOSECURE Act, which will prohibit businesses in the US from contracting with various Chinese firms on national security grounds. READ MORE
In blink-and-miss-it moment, Harris vows to expand OOP cap
In the first hour and a half of what was scheduled to be an hour and a half presidential debate, the pharma industry came up precisely zero times. Even in an extended and animated early back and forth on abortion rights, neither the moderators nor candidates asked about medication abortion, as they did in the fateful Biden-Trump debate in June. READ MORE
领英推荐
NICE clears NHS use of MSD's Welireg for genetic disorder
Patients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD's Welireg via the NHS, nearly a year after their counterparts in Scotland. READ MORE
Webinars | Live advice from pharma and biotech luminaries
Virtually convening pharma industry experts to give advice, answer questions, and help viewers understand and implement processes and technologies.
Shifting the paradigm in pharma marketing with content transformation
Join us on September 25th at 12pm EST, 5pm BST for this engaging and informative discussion with a noted customer experience and digital transformation expert.
Unlocking the Power of Storytelling in Medical Publications
Join us on September 18th at 10am ET – 3pm BST – 4pm CEST to find out why storytelling is vitally important and its definition within the scientific publications landscape.